TY - JOUR
T1 - Summary of the Japanese Respiratory Society statement for the treatment of lung cancer with comorbid interstitial pneumonia
AU - DLD/TO Assemblies of JRS
AU - Ogura, Takashi
AU - Takigawa, Nagio
AU - Tomii, Keisuke
AU - Kishi, Kazuma
AU - Inoue, Yoshikazu
AU - Ichihara, Eiki
AU - Homma, Sakae
AU - Takahashi, Kazuhisa
AU - Akamatsu, Hiroaki
AU - Ikeda, Satoshi
AU - Inase, Naohiko
AU - Iwasawa, Tae
AU - Ohe, Yuichiro
AU - Ohta, Hiromitsu
AU - Onishi, Hiroshi
AU - Okamoto, Isamu
AU - Ogawa, Kazumasa
AU - Kasahara, Kazuo
AU - Karata, Hiroki
AU - Kishimoto, Takumi
AU - Kitamura, Yuka
AU - Gemma, Akihiko
AU - Kenmotsu, Hirotsugu
AU - Sakashita, Hiroyuki
AU - Sakamoto, Susumu
AU - Sekine, Katsutoshi
AU - Takiguchi, Yuichi
AU - Tada, Yuji
AU - Toyooka, Shinichi
AU - Nakayama, Yuko
AU - Nishioka, Yasuhiko
AU - Hagiwara, Koichi
AU - Hanibuchi, Masaki
AU - Fukuoka, Junya
AU - Minegishi, Yuji
AU - Yanagihara, Toyoshi
AU - Yamamoto, Nobuyuki
AU - Yamamoto, Hiromasa
AU - Gaga, Mina
AU - Fong, Kwun M.
AU - Powell, Charles A.
AU - Kiura, Katsuyuki
N1 - Publisher Copyright:
© 2019 The Japanese Respiratory Society
PY - 2019/11
Y1 - 2019/11
N2 - Dramatic progress in targeted therapy and immunotherapy has been changing clinical practices in lung cancer. With the accumulation of clinical practice, it has become clear that pre-existing interstitial pneumonia (IP) could be a risk factor for drug-induced lung injury, which has enhanced awareness regarding the difficulty in treating lung cancer with comorbid IP. Unfortunately, there is only low-grade evidence in the field of lung cancer with comorbid IP, because almost all clinical trials exclude such patients. There have been very few specialized clinical trials for patients with lung cancer and underlying IPs thus far. Therefore, it is necessary to treat such cases empirically or to give up on the treatment itself. Considering these circumstances, establishing how to treat lung cancer with comorbid IP is an urgent issue. This paper is a summary of the official statement reported by the Diffuse Lung Disease/Thoracic Oncology Assembly and the Japanese Respiratory Society (JRS) in 2017, which attempts to approach lung cancer with comorbid IP systematically.
AB - Dramatic progress in targeted therapy and immunotherapy has been changing clinical practices in lung cancer. With the accumulation of clinical practice, it has become clear that pre-existing interstitial pneumonia (IP) could be a risk factor for drug-induced lung injury, which has enhanced awareness regarding the difficulty in treating lung cancer with comorbid IP. Unfortunately, there is only low-grade evidence in the field of lung cancer with comorbid IP, because almost all clinical trials exclude such patients. There have been very few specialized clinical trials for patients with lung cancer and underlying IPs thus far. Therefore, it is necessary to treat such cases empirically or to give up on the treatment itself. Considering these circumstances, establishing how to treat lung cancer with comorbid IP is an urgent issue. This paper is a summary of the official statement reported by the Diffuse Lung Disease/Thoracic Oncology Assembly and the Japanese Respiratory Society (JRS) in 2017, which attempts to approach lung cancer with comorbid IP systematically.
UR - http://www.scopus.com/inward/record.url?scp=85069959540&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85069959540&partnerID=8YFLogxK
U2 - 10.1016/j.resinv.2019.06.001
DO - 10.1016/j.resinv.2019.06.001
M3 - Review article
C2 - 31377122
AN - SCOPUS:85069959540
SN - 2212-5345
VL - 57
SP - 512
EP - 533
JO - Respiratory Investigation
JF - Respiratory Investigation
IS - 6
ER -